Cover Image
市場調查報告書

大流行性流感- 開發中產品分析

Pandemic Influenza - Pipeline Review, H1 2015

出版商 Global Markets Direct 商品編碼 264089
出版日期 內容資訊 英文 135 Pages
訂單完成後即時交付
價格
Back to Top
大流行性流感- 開發中產品分析 Pandemic Influenza - Pipeline Review, H1 2015
出版日期: 2015年01月30日 內容資訊: 英文 135 Pages
簡介

大流行性流感是在人類幾乎不具有免疫力的新型流感病毒出現時產生的。這個疾病很容易在人與人之間傳染,症狀有高燒、頭痛、嚴重衰弱及疲勞、肌肉及關節疼痛、伴隨咳嗽·喉嚨痛、鼻涕等呼吸系統的症狀,也可能造成支氣管炎和肺炎等併發症甚至死亡。

本報告提供大流行性流感的治療藥開發情形調查分析,提供您開發中產品的概要,臨床實驗各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

大流行性流感概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

治療藥的開發企業

  • Johnson & Johnson
  • Autoimmune Technologies, LLC
  • GlaxoSmithKline plc
  • MedImmune, LLC
  • Emergent BioSolutions Inc.
  • Lentigen Corporation
  • 武田藥品工業
  • Celltrion, Inc.
  • Novartis AG
  • Novavax, Inc.
  • OPKO Health, Inc.
  • Medicago Inc.
  • BioDiem Ltd
  • TechnoVax, Inc.
  • PDS Biotechnology Corporation
  • Theraclone Sciences, Inc.
  • Sinovac Biotech Ltd.
  • NanoBio Corporation
  • Protein Sciences Corporation
  • Immunovaccine, Inc.
  • VaxInnate Corporation
  • UMN Pharma Inc.
  • Sirnaomics, Inc.
  • AIMM Therapeutics B.V.
  • Cilian AG
  • AmVac AG
  • TSRL, Inc.
  • AltraVax Inc.
  • Big DNA Ltd.
  • ContraFect Corporation
  • PeptiVir, Inc.
  • Pike Pharma GmbH
  • Codagenix, Inc.

治療藥的評估

  • 單獨療法的產品
  • 聯合治療的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • KIB-PCI
  • Live Attenuated Influenza Vaccine
  • UMN-0501
  • Subunit Vaccine for H5N1 Influenza
  • TCN-032
  • CTP-27
  • VX-787
  • Pandemic Influenza Vaccine H5N1
  • Pandemic Influenza Vaccine H7N9 (Monovalent)
  • MEDI-550
  • flu pandemic (H5N1) vaccine
  • VAX-161
  • VAX-16101C
  • MEDI-9287
  • Vaccine for H7N9 Influenza
  • Flu Vaccine
  • LG-611
  • Subunit Vaccine for H5N1 Pandemic Influenza
  • STP-702
  • TVX-002
  • Influenza VLP Vaccine
  • MVA-H5HA
  • Flufirvitide-3
  • Anti-H5HA mAB
  • Monoclonal Antibodies to Target Hemagglutinin for Seasonal Influenza and Pandemic Influenza
  • CF-404
  • Pandemic Influenza Vaccine
  • AMV-411
  • CiFlu
  • Bispecific Monoclonal Antibody for Seasonal and Pandemic Influenza
  • UMN-0901
  • TSR-026
  • PDS-0102
  • Pandemic Influenza Vaccine
  • IKT-041
  • Pandemic Influenza Vaccine
  • H7N9 VLP Vaccine + Glucopyranosyl Lipid A Adjuvant
  • PVI-1000
  • A-06
  • BDNA-002
  • LIAVM-2eHD
  • Pan-Flu
  • Pandemic Influenza Vaccine
  • CTP-25
  • Universal Vaccine for Seasonal and Pandemic Influenza
  • TSR-462
  • Monoclonal Antibodies to Inhibit Hemagglutinin for Pandemic Influenza
  • Small Molecules to Inhibit Viral Polymerase for Influenza
  • Pandemic Infleunza Vaccine
  • Vaccine for Pandemic Influenza
  • Vaccine for Pandemic Influenza

開發中產品的最新趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC6141IDB

Summary

Global Markets Direct's, 'Pandemic Influenza - Pipeline Review, H1 2015', provides an overview of the Pandemic Influenza's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pandemic Influenza, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pandemic Influenza and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pandemic Influenza
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Pandemic Influenza and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Pandemic Influenza products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Pandemic Influenza pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Pandemic Influenza
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Pandemic Influenza pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Pandemic Influenza Overview
  • Therapeutics Development
    • Pipeline Products for Pandemic Influenza - Overview
    • Pipeline Products for Pandemic Influenza - Comparative Analysis
  • Pandemic Influenza - Therapeutics under Development by Companies
  • Pandemic Influenza - Therapeutics under Investigation by Universities/Institutes
  • Pandemic Influenza - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Pandemic Influenza - Products under Development by Companies
  • Pandemic Influenza - Products under Investigation by Universities/Institutes
  • Pandemic Influenza - Companies Involved in Therapeutics Development
    • AIMM Therapeutics B.V.
    • AltraVax Inc.
    • AmVac AG
    • Big DNA Ltd.
    • BioDiem Ltd
    • Celltrion, Inc.
    • Cilian AG
    • Codagenix, Inc.
    • ContraFect Corporation
    • Emergent BioSolutions Inc.
    • GlaxoSmithKline plc
    • Hemispherx Biopharma, Inc.
    • Immunovaccine, Inc.
    • Johnson & Johnson
    • Medicago Inc.
    • NanoBio Corporation
    • Novartis AG
    • Novavax, Inc.
    • OPKO Health, Inc.
    • PDS Biotechnology Corporation
    • PeptiVir, Inc.
    • Protein Sciences Corporation
    • Sinovac Biotech Ltd.
    • Sirnaomics, Inc.
    • TaiGen Biotechnology Co., Ltd.
    • TechnoVax, Inc.
    • Theraclone Sciences, Inc.
    • TSRL, Inc.
    • UMN Pharma Inc.
    • VaxInnate Corporation
  • Pandemic Influenza - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • A-06 - Drug Profile
    • Alferon LDO - Drug Profile
    • AMV-411 - Drug Profile
    • BDNA-002 - Drug Profile
    • Bispecific Monoclonal Antibody to Inhibit Hemagglutinin for Seasonal and Pandemic Influenza - Drug Profile
    • CF-404 - Drug Profile
    • CiFlu - Drug Profile
    • CTP-25 - Drug Profile
    • CTP-27 - Drug Profile
    • flu pandemic (H5N1) vaccine - Drug Profile
    • IKT-041 - Drug Profile
    • influenza (H5) vaccine - Drug Profile
    • influenza [H7N9] virus like particle vaccine + Glucopyranosyl Lipid A Adjuvant - Drug Profile
    • influenza [strain H5N1] (monovalent) vaccine - Drug Profile
    • influenza [strain H7N9] (monovalent) vaccine - Drug Profile
    • influenza vaccine - Drug Profile
    • influenza vaccine - Drug Profile
    • influenza vaccine - Drug Profile
    • influenza vaccine - Drug Profile
    • Monoclonal Antibodies to Inhibit Hemagglutinin for Pandemic Influenza - Drug Profile
    • Monoclonal Antibodies to Inhibit Hemagglutinin for Seasonal Influenza and Pandemic Influenza - Drug Profile
    • Monoclonal Antibody to Inhibit Hemagglutinin for Influenza - Drug Profile
    • MVAH-5HA - Drug Profile
    • pandemic infleunza vaccine - Drug Profile
    • pandemic influenza [H5N1] vaccine - Drug Profile
    • pandemic influenza [H7N9] (monovalent) vaccine - Drug Profile
    • pandemic influenza vaccine - Drug Profile
    • pandemic influenza vaccine - Drug Profile
    • pandemic influenza vaccine - Drug Profile
    • pandemic influenza vaccine - Drug Profile
    • pandemic influenza vaccine - Drug Profile
    • pandemic influenza vaccine - Drug Profile
    • pandemic influenza vaccine [H5N1] - Drug Profile
    • PDS-0102 - Drug Profile
    • PVI-1000 - Drug Profile
    • Small Molecules for Influenza - Drug Profile
    • Small Molecules for Influenza - Drug Profile
    • Small Molecules for Pandemic Influenza - Drug Profile
    • STP-702 - Drug Profile
    • TCN-032 - Drug Profile
    • TSR-026 - Drug Profile
    • TSR-462 - Drug Profile
    • TVX-002 - Drug Profile
    • UMN-0501 - Drug Profile
    • UMN-0901 - Drug Profile
    • VAX-161 - Drug Profile
    • VAX-16101C - Drug Profile
    • VX-787 - Drug Profile
  • Pandemic Influenza - Recent Pipeline Updates
  • Pandemic Influenza - Dormant Projects
  • Pandemic Influenza - Discontinued Products
  • Pandemic Influenza - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Pandemic Influenza, H1 2015
  • Number of Products under Development for Pandemic Influenza - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Number of Products under Development by Companies, H1 2015 (Contd..1)
  • Number of Products under Development by Companies, H1 2015 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H1 2015
  • Comparative Analysis by Clinical Stage Development, H1 2015
  • Comparative Analysis by Early Stage Development, H1 2015
  • Comparative Analysis by Unknown Stage Development, H1 2015
  • Products under Development by Companies, H1 2015
  • Products under Development by Companies, H1 2015 (Contd..1)
  • Products under Development by Companies, H1 2015 (Contd..2)
  • Products under Investigation by Universities/Institutes, H1 2015
  • Pandemic Influenza - Pipeline by AIMM Therapeutics B.V., H1 2015
  • Pandemic Influenza - Pipeline by AltraVax Inc., H1 2015
  • Pandemic Influenza - Pipeline by AmVac AG, H1 2015
  • Pandemic Influenza - Pipeline by Big DNA Ltd., H1 2015
  • Pandemic Influenza - Pipeline by BioDiem Ltd, H1 2015
  • Pandemic Influenza - Pipeline by Celltrion, Inc., H1 2015
  • Pandemic Influenza - Pipeline by Cilian AG, H1 2015
  • Pandemic Influenza - Pipeline by Codagenix, Inc., H1 2015
  • Pandemic Influenza - Pipeline by ContraFect Corporation, H1 2015
  • Pandemic Influenza - Pipeline by Emergent BioSolutions Inc., H1 2015
  • Pandemic Influenza - Pipeline by GlaxoSmithKline plc, H1 2015
  • Pandemic Influenza - Pipeline by Hemispherx Biopharma, Inc., H1 2015
  • Pandemic Influenza - Pipeline by Immunovaccine, Inc., H1 2015
  • Pandemic Influenza - Pipeline by Johnson & Johnson, H1 2015
  • Pandemic Influenza - Pipeline by Medicago Inc., H1 2015
  • Pandemic Influenza - Pipeline by NanoBio Corporation, H1 2015
  • Pandemic Influenza - Pipeline by Novartis AG, H1 2015
  • Pandemic Influenza - Pipeline by Novavax, Inc., H1 2015
  • Pandemic Influenza - Pipeline by OPKO Health, Inc., H1 2015
  • Pandemic Influenza - Pipeline by PDS Biotechnology Corporation, H1 2015
  • Pandemic Influenza - Pipeline by PeptiVir, Inc., H1 2015
  • Pandemic Influenza - Pipeline by Protein Sciences Corporation, H1 2015
  • Pandemic Influenza - Pipeline by Sinovac Biotech Ltd., H1 2015
  • Pandemic Influenza - Pipeline by Sirnaomics, Inc., H1 2015
  • Pandemic Influenza - Pipeline by TaiGen Biotechnology Co., Ltd., H1 2015
  • Pandemic Influenza - Pipeline by TechnoVax, Inc., H1 2015
  • Pandemic Influenza - Pipeline by Theraclone Sciences, Inc., H1 2015
  • Pandemic Influenza - Pipeline by TSRL, Inc., H1 2015
  • Pandemic Influenza - Pipeline by UMN Pharma Inc., H1 2015
  • Pandemic Influenza - Pipeline by VaxInnate Corporation, H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Assessment by Combination Products, H1 2015
  • Number of Products by Stage and Target, H1 2015
  • Number of Products by Stage and Mechanism of Action, H1 2015
  • Number of Products by Stage and Route of Administration, H1 2015
  • Number of Products by Stage and Molecule Type, H1 2015
  • Pandemic Influenza Therapeutics - Recent Pipeline Updates, H1 2015
  • Pandemic Influenza - Dormant Projects, H1 2015
  • Pandemic Influenza - Dormant Projects (Contd..1), H1 2015
  • Pandemic Influenza - Discontinued Products, H1 2015

List of Figures

  • Number of Products under Development for Pandemic Influenza, H1 2015
  • Number of Products under Development for Pandemic Influenza - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Number of Products under Investigation by Universities/Institutes, H1 2015
  • Comparative Analysis by Clinical Stage Development, H1 2015
  • Comparative Analysis by Early Stage Products, H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Number of Products by Top 10 Targets, H1 2015
  • Number of Products by Stage and Top 10 Targets, H1 2015
  • Number of Products by Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Top 10 Routes of Administration, H1 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2015
  • Number of Products by Top 10 Molecule Types, H1 2015
  • Number of Products by Stage and Top 10 Molecule Types, H1 2015
Back to Top